Across TCGA pan-cancer cohorts, AIP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AIP data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher AIP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AIP expression acts as an unfavorable survival marker.
UCS are the cancer types where AIP Mutation most reproducibly stratifies survival.